Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR
Top Cited Papers
- 4 June 2004
- Vol. 59 (7) , 709-717
- https://doi.org/10.1111/j.1398-9995.2004.00550.x
Abstract
Background: Anti‐IgE therapy could be particularly beneficial for patients with concomitant disease as it targets a common factor in both diseases. The aim of this study was to evaluate the efficacy and safety of omalizumab in patients with concomitant moderate‐to‐severe asthma and persistent allergic rhinitis.Methods: This multicentre, randomized, double‐blind, parallel‐group, placebo‐controlled trial evaluated the safety and efficacy of omalizumab. A total of 405 patients (12–74 years) with a stable treatment (≥ 400 μg budesonide Turbuhaler®) and ≥ 2 unscheduled medical visits for asthma during the past year or ≥ 3 during the past 2 years were enrolled. Patients received omalizumab (≥ 0.016 mg/kg/IgE [IU/ml] per 4 weeks) or placebo for 28 weeks.Results: Fewer patients treated with omalizumab experienced asthma exacerbations (20.6%) than placebo‐treated patients (30.1%), P = 0.02. A clinically significant (≥ 1.0 point) improvement in both Asthma Quality of Life Questionnaire and Rhinitis Quality of Life Questionnaire occurred in 57.7% of omalizumab patients compared with 40.6% of placebo patients (P < 0.001). Omalizumab reduced Wasserfallen symptom scores for asthma (P = 0.023), rhinitis (P < 0.001) and the composite asthma/rhinitis scores (P < 0.001) compared with placebo. Serious adverse events were observed in 1.4% of omalizumab‐treated patients and 1.5% of placebo‐treated patients.Conclusion: Omalizumab is well tolerated and effective in preventing asthma exacerbations and improving quality of life in patients with concomitant asthma and persistent allergic rhinitis.Keywords
This publication has 36 references indexed in Scilit:
- Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitisPublished by Elsevier ,2003
- Omalizumab is effective in the long-term control of severe allergic asthmaAnnals of Allergy, Asthma & Immunology, 2003
- Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and MortalityCurrent Medical Research and Opinion, 2001
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and MortalityCurrent Medical Research and Opinion, 2001
- Serum immunoglobulin E levels predict human airway reactivity in vitroClinical and Experimental Allergy, 2000
- Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trialsJournal of Allergy and Clinical Immunology, 1997
- Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnairesJournal of Allergy and Clinical Immunology, 1997
- A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal sprayJournal of Allergy and Clinical Immunology, 1996
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994